A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Phase of Trial: Phase IV
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 09 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Oct 2015 Planned initiation date changed from 1 Sep 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
- 31 Jul 2015 New trial record